EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Clinical applications of oligonucleotides for cancer therapy

Vittorio DeFranciscis, Giovanni Amabile, Marcin Kortylewski

Molecular Therapy · 2025-06 · 33 (6) · 2705-2718

DOI: 10.1016/j.ymthe.2025.02.045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025-06. Verfasst von Vittorio DeFranciscis und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Research Council, Institute of Genetic and Biomedical Research, Milan, Italy. Hauptthemen laut MEDLINE: Neoplasms, Oligonucleotides, Genetic Therapy. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, US Department of Defense, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oligonucleotide therapeutics (ONTs) represent a rapidly evolving modality for cancer treatment, capitalizing on their ability to modulate gene expression with high specificity. With more than 20 nucleic acid-based therapies that gained regulatory approval, advances in chemical modifications, sequence optimization, and novel delivery systems have propelled ONTs from research tools to clinical realities. ONTs, including siRNAs, antisense oligonucleotides, saRNA, miRNA, aptamers, and decoys, offer promising solutions for targeting previously "undruggable" molecules, such as transcription factors, and enhancing cancer immunotherapy by overcoming tumor immune evasion. The promise of ONT application in cancer treatment is exemplified by the recent FDA approval of the first oligonucleotide-based treatment to myeloproliferative disease. At the same time, there are challenges in delivering ONTs to specific tissues, mitigating off-target effects, and improving cellular uptake and endosomal release. This review provides a comprehensive overview of ONTs in clinical trials, emerging delivery strategies, and innovative therapeutic approaches, emphasizing the role of ONTs in immunotherapy and addressing hurdles that hinder their clinical translation. By examining advances and remaining challenges, we highlight opportunities for ONTs to revolutionize oncology and enhance patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsOligonucleotidesGenetic TherapyHumansImmunotherapyClinical Trials as TopicAnimalsOligonucleotides, AntisenseDrug Delivery Systems

Stichwörter der Autor:innen

antisense oligonucleotidesaptamerscancer therapydeliveryimmunotherapyoligonucleotidesiRNA

Substanzen

OligonucleotidesOligonucleotides, Antisense

Autor:innen und Institutionen

  • National Research Council, Institute of Genetic and Biomedical Research, Milan, Italy.
  • AptaDiR Therapeutics, 20121 Milan, Italy.
  • Department of Immuno-Oncology, Beckman Research Institute at City of Hope National Medical Center, Duarte, CA 91010, USA. Electronic address: mkortylewski@coh.org.

Förderung

  • NCI NIH HHS
  • US Department of Defense
  • National Institutes of Health
  • National Institutes of Health National Cancer Institute

Zitieren

APA

DeFranciscis, V., Amabile, G., & Kortylewski, M. (2025). Clinical applications of oligonucleotides for cancer therapy. Molecular Therapy, 33(6), 2705-2718. https://doi.org/10.1016/j.ymthe.2025.02.045

Vancouver

DeFranciscis V, Amabile G, Kortylewski M. Clinical applications of oligonucleotides for cancer therapy. Molecular Therapy. 2025;33(6):2705-2718. doi:10.1016/j.ymthe.2025.02.045

BibTeX
@article{DeFranciscis2025,
  author = {DeFranciscis, Vittorio and Amabile, Giovanni and Kortylewski, Marcin},
  title = {Clinical applications of oligonucleotides for cancer therapy},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {6},
  pages = {2705--2718},
  doi = {10.1016/j.ymthe.2025.02.045}
}
Kostenlos starten →